57 research outputs found
Subregional 6-[18F]fluoro-ʟ-m-tyrosine Uptake in the Striatum in Parkinson's Disease
<p>Abstract</p> <p>Background</p> <p>In idiopathic Parkinson's disease (PD) the clinical features are heterogeneous and include different predominant symptoms. The aim of the present study was to determine the relationship between subregional aromatic l-amino acid decarboxylase (AADC) activity in the striatum and the cardinal motor symptoms of PD using high-resolution positron emission tomography (PET) with an AADC tracer, 6-[<sup>18</sup>F]fluoro-ʟ-<it>m</it>-tyrosine (FMT).</p> <p>Methods</p> <p>We assessed 101 patients with PD and 19 healthy volunteers. PD was diagnosed based on the UK Brain Bank criteria by two experts on movement disorders. Motor symptoms were measured with the Unified Parkinson's Disease Rating Scale (UPDRS). FMT uptake in the subregions of the striatum was analyzed using semi-automated software for region-of-interest demarcation on co-registered magnetic resonance images.</p> <p>Results</p> <p>In all PD patients, FMT uptake was decreased in the posterior putamen regardless of predominant motor symptoms and disease duration. Smaller uptake values were found in the putamen contralateral to the side with more affected limbs. The severity of bradykinesia, rigidity, and axial symptoms was correlated with the decrease of FMT uptake in the putamen, particularly in the anterior part. No significant correlation was observed between tremors and FMT uptake.</p> <p>Conclusions</p> <p>Decrease of FMT uptake in the posterior putamen appears to be most sensitive in mild PD and uptake in the anterior putamen may reflect the severity of main motor symptoms, except for tremor.</p
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD. Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clinical benefits in recent high-profile clinical trials. This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clinical trials. Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estimation of efficacy is further hampered by the absence of validated biomarkers of disease progression. Drug development in PD dementia has been mostly unsuccessful; however, emerging biochemical, genetic and pathological evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention. This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD
Recommended from our members
Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous.
BACKGROUND: Procedural aspects and complications of gastrojejunostomy insertion are important considerations in the use of levodopa-carbidopa intestinal gel therapy (LCIG) and may limit uptake. We describe our experience of using per-oral image guided gastrojejunostomy (PIG-J) which avoids the need for endoscopy and routine sedation in percutaneous endoscopic gastrojejunostomy (PEG-J) and allows more secure tube placement than radiologically inserted gastrojejunostomy techniques. METHODS: We describe a case series of 32 patients undergoing PIG-J insertion for LCIG therapy in a single centre. Under local anaesthetic, a fluoroscopy-guided gastric puncture allows access for the guidewire which is then used to pull through the gastrostomy tube allowing for secure fixation, followed by placement of the gastrojejunal extension. RESULTS: Between December 2015 to April 2020, 32/34 patients referred for PIG-J underwent this procedure successfully, 2 cases unsuccessful due to technical considerations. One patient developed delirium following successful implantation. Ten patients (31%) required a replacement tube due to blockage or displacement within the first 12 months of placement, including 2 patients who needed more than one replacement. Minor complications occurred in 10 other patients (31%), including infection (9 patients); a small haematoma not requiring intervention who later developed an infection (1 patient); and peri-stomal acid leakage (1 patient). CONCLUSION: In summary, PIG-J insertion is safe with a similar complication rate to traditional PEG-J, well tolerated and effective for use in LCIG administration. This may widen access to LCIG for PD patients who may not be suitable or unable to tolerate PEG-J
A study of oriented conductive composites with segregated network structure obtained via solid‐state processing of UHMWPE reactor powder and carbon nanofillers
Trends on New Biodegradable Blends on the Basis of Copolymers 3-Hydroxybutyrate with Hydroxyvalerate and Segmented Polyetherurethane
Temperature dependence of the strength of adhesive joints based on crystalline polymer adhesives
IMMUNE PARAMETERS IN PATIENTS WITH BREAST CANCER AFTER RADIOTHERAPY AND SURGICAL TREATMENT
Abstract. Some immune parameters (cell subsets in peripheral blood, spontaneous and LPS-induce production of IL-1β, IL-5, IL-7, IL-12, IL-13, IL-17, G-CSF, MCP-1 and MIP-1β in whole blood cultures) were studied in fifty patients with breast cancer (T2-3, N0-3, M0) after radiation therapy and surgical treatment. A significant decrease in lymphocytes, CD3+ and CD4+T-cell counts, CD19+B-lymphocytes, erythrocytes, hemoglobin level, and amounts of phagocytic cells was revealed. The cytokine status was characterized by prevalence of pro-inflammatory cytokines (IL-1β, IL-12, IL-17) and chemokines (MCP-1, MIP-1β), accompanied by low levels of Th2/ anti-inflammatory IL-13. Furthermore, a markedly increased production of G-CSF and IL-7 was found, thus apparently pointing to the switching of a compensatory mechanisms in response to cytoreductive effects of anti-tumor therapy. IL-7 levels in lymphopenic patients (< 1.2 х 109/L; a mean of 0.81±0.11) were significantly higher than that in an opposite group of lymphopenia-free women (> 1.2 х 109/L; a mean of 1.34±0.01). An inverse correlation (rS = –0,88; p < 0,0001) between blood lymphocyte counts and IL-7 levels allows us to suggest a mechanism of homeostatic peripheral expansion (HPE) to be involved in maintenance and restoration ofT cell homeostasis in the patients treated for breast cancer. Significance of HPE mechanism for induction of both beneficial protective tumor-specific autoimmunity and increased risk of autoimmune complications is discussed
- …